Search Results

Displaying Results 101-103 of 103 "'ASO'"

Jun 26, 2025, 08:30 ET Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

Together, the organizations aim to drive awareness, and secure payer contracts, through a robust multi-channel marketing plan designed to engage Commercial, ASO ('Administrative Services Only'), Medicaid, and Medicare Advantage plans, as well as self-funded employers, consultants, brokers, and value-based care

More news about: DarioHealth Corp.


Jun 10, 2025, 08:00 ET Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S).

More news about: Vanda Pharmaceuticals Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.